Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

756 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Waldenstrom macroglobulinemia.
Leleu X, Roccaro AM, Moreau AS, Dupire S, Robu D, Gay J, Hatjiharissi E, Burwik N, Ghobrial IM. Leleu X, et al. Among authors: gay j. Cancer Lett. 2008 Oct 18;270(1):95-107. doi: 10.1016/j.canlet.2008.04.040. Epub 2008 Jun 13. Cancer Lett. 2008. PMID: 18555588 Free PMC article.
Update on therapeutic options in Waldenström macroglobulinemia.
Leleu X, Gay J, Roccaro AM, Moreau AS, Poulain S, Dulery R, Champs BB, Robu D, Ghobrial IM. Leleu X, et al. Among authors: gay j. Eur J Haematol. 2009 Jan;82(1):1-12. doi: 10.1111/j.1600-0609.2008.01171.x. Eur J Haematol. 2009. PMID: 19087134 Free PMC article. Review.
Bortezomib and Waldenstrom's macroglobulinemia.
Pascal L, Gay J, Willekens C, Wemeau M, Balkaran S, Robu D, Roccaro A, Morel P, Ghobrial I, Leleu X. Pascal L, et al. Among authors: gay j. Expert Opin Pharmacother. 2009 Apr;10(5):909-16. doi: 10.1517/14656560902800160. Expert Opin Pharmacother. 2009. PMID: 19351237 Review.
IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.
Boyle E, Manier S, Lejeune J, Fouquet G, Guidez S, Bonnet S, Debarri H, Demarquette H, Dulery R, Gay J, Hennache B, Onraed B, Faucompré JL, Schraen S, Facon T, Avet-Loiseau H, Chevret S, Leblond V, Harding S, Leleu X. Boyle E, et al. Among authors: gay j. Clin Cancer Res. 2016 Oct 15;22(20):5152-5158. doi: 10.1158/1078-0432.CCR-15-2899. Epub 2016 May 11. Clin Cancer Res. 2016. PMID: 27169996
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
756 results